<DOC>
	<DOC>NCT02127775</DOC>
	<brief_summary>This study will assess the bioequivalence of lesinurad tablets manufactured at two different sites.</brief_summary>
	<brief_title>Lesinurad Tablet Bioequivalence</brief_title>
	<detailed_description>This study is intended to evaluate the clinical comparability of lesinurad tablets manufactured at the 2 different sites by assessing relevant clinical Pharmacokinetics (PK) parameters.</detailed_description>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2. Subject has a Screening serum urate level ≤ 7 mg/dL. ˗ Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment. Subject has any gastrointestinal disorder that affects motility and/or absorption. Subject has a history or suspicion of kidney stones. Subject has undergone major surgery within 3 months prior to Screening. Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening visit. Subject has inadequate venous access or unsuitable veins for repeated venipuncture.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>